260 related articles for article (PubMed ID: 27285519)
1. The Conundrum of Online Prescription Drug Promotion Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Wanasika I
Int J Health Policy Manag; 2016 Mar; 5(6):391-2. PubMed ID: 27285519
[TBL] [Abstract][Full Text] [Related]
2. Considering the Future of Pharmaceutical Promotions in Social Media Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Carpentier FR
Int J Health Policy Manag; 2016 Feb; 5(4):283-5. PubMed ID: 27239874
[TBL] [Abstract][Full Text] [Related]
3. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: Teaching Drug Marketers How to Inform Better or Spin Better? Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Doran E
Int J Health Policy Manag; 2016 Feb; 5(5):333-5. PubMed ID: 27239884
[TBL] [Abstract][Full Text] [Related]
4. Still the Great Debate - "Fair Balance" in Direct-to-Consumer Prescription Drug Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Rollins BL
Int J Health Policy Manag; 2016 Feb; 5(4):287-8. PubMed ID: 27239875
[TBL] [Abstract][Full Text] [Related]
5. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
Kim H
Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
[TBL] [Abstract][Full Text] [Related]
6. The Tip of the Iceberg of Misleading Online Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Mintzes B
Int J Health Policy Manag; 2016 Feb; 5(5):329-31. PubMed ID: 27239883
[TBL] [Abstract][Full Text] [Related]
7. Digital Direct-to-Consumer Advertising: A Perfect Storm of Rapid Evolution and Stagnant Regulation Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Mackey TK
Int J Health Policy Manag; 2016 Feb; 5(4):271-4. PubMed ID: 27239871
[TBL] [Abstract][Full Text] [Related]
8. Future Challenges and Opportunities in Online Prescription Drug Promotion Research Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Southwell BG; Rupert DJ
Int J Health Policy Manag; 2016 Jan; 5(3):211-3. PubMed ID: 26927597
[TBL] [Abstract][Full Text] [Related]
9. The federal regulation of prescription drug advertising and promotion.
Kessler DA; Pines WL
JAMA; 1990 Nov; 264(18):2409-15. PubMed ID: 2231998
[TBL] [Abstract][Full Text] [Related]
10. Regulation of prescription drug promotion: direct-to-consumer advertising.
Baylor-Henry M; Drezin NA
Clin Ther; 1998; 20 Suppl C():C86-95. PubMed ID: 9915094
[TBL] [Abstract][Full Text] [Related]
11. Fair Balance and Adequate Provision in Direct-to-Consumer Prescription Drug Online Banner Advertisements: A Content Analysis.
Adams C
J Med Internet Res; 2016 Feb; 18(2):e33. PubMed ID: 26892749
[TBL] [Abstract][Full Text] [Related]
12. Promotion of prescription drugs to consumers.
Rosenthal MB; Berndt ER; Donohue JM; Frank RG; Epstein AM
N Engl J Med; 2002 Feb; 346(7):498-505. PubMed ID: 11844852
[TBL] [Abstract][Full Text] [Related]
13. Examining the FDA's oversight of direct-to-consumer advertising.
Gahart MT; Duhamel LM; Dievler A; Price R
Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-120-3. PubMed ID: 14527243
[TBL] [Abstract][Full Text] [Related]
14. Is the information "fair and balanced" in direct-to-consumer prescription drug websites?
Huh J; Cude BJ
J Health Commun; 2004; 9(6):529-40. PubMed ID: 15764451
[TBL] [Abstract][Full Text] [Related]
15. Direct-to-consumer prescription drug advertising: history, regulation, and issues.
Huh J; DeLorme DE; Reid LN; An S
Minn Med; 2010 Mar; 93(3):50-2. PubMed ID: 20429178
[TBL] [Abstract][Full Text] [Related]
16. The educational potential of direct-to-consumer prescription drug advertising.
Kaphingst KA; DeJong W
Health Aff (Millwood); 2004; 23(4):143-50. PubMed ID: 15318574
[TBL] [Abstract][Full Text] [Related]
17. Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication.
Bradford WD; Kleit AN
Health Econ; 2015 Jul; 24(7):859-75. PubMed ID: 25059655
[TBL] [Abstract][Full Text] [Related]
18. A decade of direct-to-consumer advertising of prescription drugs.
Donohue JM; Cevasco M; Rosenthal MB
N Engl J Med; 2007 Aug; 357(7):673-81. PubMed ID: 17699817
[TBL] [Abstract][Full Text] [Related]
19. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.
Klara K; Kim J; Ross JS
J Gen Intern Med; 2018 May; 33(5):651-658. PubMed ID: 29484575
[TBL] [Abstract][Full Text] [Related]
20. A Legislative/Legal History of Prescription Drug Advertising and Promotion Regulation.
Li S; Gibbs I
J Pharm Pharm Sci; 2021; 24():381-389. PubMed ID: 34314671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
